219 related articles for article (PubMed ID: 26077281)
1. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
[TBL] [Abstract][Full Text] [Related]
4. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
Ma H; Lu J; Song Y; Wang H; Yin S
BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.
Zhang H; Chen L; Wu L; Huang J; Li H; Wang X; Weng H
Medicine (Baltimore); 2020 Apr; 99(16):e19493. PubMed ID: 32311922
[TBL] [Abstract][Full Text] [Related]
7. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
[TBL] [Abstract][Full Text] [Related]
8. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
[TBL] [Abstract][Full Text] [Related]
9. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study.
Oguz EO; Kucuksahin O; Turgay M; Yildizgoren MT; Ates A; Demir N; Kumbasar OO; Kinikli G; Duzgun N
Clin Rheumatol; 2016 Mar; 35(3):663-6. PubMed ID: 26758437
[TBL] [Abstract][Full Text] [Related]
10. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
[TBL] [Abstract][Full Text] [Related]
11. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
12. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
13. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
Kuwana M; Shirai Y; Takeuchi T
J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
[TBL] [Abstract][Full Text] [Related]
14. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
[TBL] [Abstract][Full Text] [Related]
15. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.
Ishikawa N; Hattori N; Yokoyama A; Kohno N
Respir Investig; 2012 Mar; 50(1):3-13. PubMed ID: 22554854
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical performance of the HISCL-5000 analyzer in the detection of Krebs von den Lungen-6 antigen and its diagnostic value in interstitial lung disease.
Wang J; Huang Z; Xue M; Huang H; Zheng X; Zhong N; Sun B
J Clin Lab Anal; 2020 Feb; 34(2):e23070. PubMed ID: 31691368
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.
Satoh H; Kurishima K; Ishikawa H; Ohtsuka M
J Intern Med; 2006 Nov; 260(5):429-34. PubMed ID: 17040248
[TBL] [Abstract][Full Text] [Related]
18. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
[TBL] [Abstract][Full Text] [Related]
19. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.
Hamada T; Samukawa T; Kumamoto T; Hatanaka K; Tsukuya G; Yamamoto M; Machida K; Watanabe M; Mizuno K; Higashimoto I; Inoue Y; Inoue H
BMC Pulm Med; 2015 Sep; 15():110. PubMed ID: 26424433
[TBL] [Abstract][Full Text] [Related]
20. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study.
Kilinc AA; Arslan A; Yildiz M; Kucur M; Adrovic A; Barut K; Sahin S; Cokugras H; Kasapcopur O
Rheumatol Int; 2020 Oct; 40(10):1701-1706. PubMed ID: 31784789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
